Can Fite Biopharma Ltd
CANF
View Detailed Chart
0.396USD
-0.013-3.23%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
1.57BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.23%
5 Days
-3.54%
1 Month
-25.38%
6 Months
-64.37%
Year to Date
-75.66%
1 Year
-81.26%
View Detailed Chart
TradingKey Stock Score of Can Fite Biopharma Ltd
Currency: USD Updated: 2025-11-11Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Can Fite Biopharma Ltd's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
11.167
Target Price
+2632.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Can Fite Biopharma Ltd Highlights
StrengthsRisks
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Growing
The company is in a growing phase, with the latest annual income totaling USD 674.00K.
Overvalued
The company’s latest PE is -0.46, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 944.19K shares, increasing 4.12% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.49.
Can Fite Biopharma Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Can Fite Biopharma Ltd Info
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Ticker SymbolCANF
CompanyCan Fite Biopharma Ltd
CEODr. Pnina Fishman, Ph.D.
Websitehttps://www.canfite.com/
Related Instruments
+2.27%
+2.88%
+2.95%
+1.84%
+2.59%
+4.84%
+4.57%
+6.99%
+3.73%
+4.59%
+2.03%
+1.90%
-0.34%
+3.09%
+2.22%
+2.93%
0.00%
+3.03%
+2.32%
+2.28%Popular Symbols
